{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Goldvaser H"],"funding":["NCI NIH HHS"],"pagination":["167-177"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12353014"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["210(1)"],"pubmed_abstract":["Purpose
To evaluate the association between the HER2 score as provided by the Oncotype DX Recurrence Score (RS) assay, tumor characteristics, and outcomes in early-stage, ER + HER2-negative breast cancer (BC).Methods
All women insured by the Clalit Health Services, with early-stage, ER + HER2-negative BC who underwent RS testing between 2008 and 2011 were included. Patient/tumor characteristics and Kaplan-Meier estimates for distant recurrence-free survival (DRFS) and overall survival (OS) were compared by HER2 category, based on the HER2 score provided by the RS assay: lower HER2 score group representing the lower third of the HER2 score range (≤ 8.5); higher HER2 score group representing the upper 2 thirds of the HER2 score range (8.6-10.7).Results
1535 patients w"],"journal":["Breast cancer research and treatment"],"pubmed_title":["ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes."],"pmcid":["PMC12353014"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Drumea K","Evron E","Toker M","Gal-Yam E","Sela GB","Yerushalmi R","Mutai R","Paluch-Shimon S","Merose R","Shai A","Sonnenblick A","Soussan-Gutman L","Stemmer SM","Bareket-Samish A","Goldvaser H","Kuchuk I"],"additional_accession":[]},"is_claimable":false,"name":"ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.","description":"Purpose
To evaluate the association between the HER2 score as provided by the Oncotype DX Recurrence Score (RS) assay, tumor characteristics, and outcomes in early-stage, ER + HER2-negative breast cancer (BC).Methods
All women insured by the Clalit Health Services, with early-stage, ER + HER2-negative BC who underwent RS testing between 2008 and 2011 were included. Patient/tumor characteristics and Kaplan-Meier estimates for distant recurrence-free survival (DRFS) and overall survival (OS) were compared by HER2 category, based on the HER2 score provided by the RS assay: lower HER2 score group representing the lower third of the HER2 score range (≤ 8.5); higher HER2 score group representing the upper 2 thirds of the HER2 score range (8.6-10.7).Results
1535 patients w","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-05-29T15:08:32.28Z","creation":"2026-04-08T05:11:47.514Z"},"accession":"S-EPMC12353014","cross_references":{"pubmed":["39560822"],"doi":["10.1007/s10549-024-07549-7"]}}